Results 121 to 130 of about 27,150 (219)

COVID19‐Related Onset and Relapses of Juvenile Systemic Lupus Erythematosus‐Like Disease

Journal of Paediatrics and Child Health, EarlyView.
Chiara Cannata, Francesca Tirelli, Alessandra Meneghel, Francesco Zulian   +3 more
wiley   +1 more source

Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocol study [PDF]

, 2017
Introduction: Acute gout occurs in people with chronic kidney disease, who are commonly older people with comorbidities such as hypertension, heart disease and diabetes.
Ahmed, Khalid, Almond, Mike, Balasubramaniam, Gowrie, Bhagat, Sweta, Dasgupta, Bhaskar, Harnett, Patrick, Harrison, Michael, Mallen, Christian, Marianayagam, Thiraupathy, Parker, Mike, Parker, Trisha, Pitzalis, Costantino, Roddy, Edward, Scales, Jonathan, Turner, David   +14 more
core   +2 more sources

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

Drug Design, Development and Therapy, 2014
Dongsheng Hong,1 Zhihai Yang,1 Shuyin Han,1 Xingguang Liang,1 Kuifen Ma,1 Xingguo Zhang1,2 1Department of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, 2College of Pharmaceutical Science, Zhejiang Chinese Medical ...
Hong D, Yang Z, Han SY, Liang X, Ma K, Zhang X   +5 more
doaj  

Association of SIRT6 Expression With Risk of Pneumonitis Induced by Radiotherapy in Cancer Patients

Molecular Carcinogenesis, Volume 64, Issue 6, Page 1104-1118, June 2025.
ABSTRACT Thoracic tumours represent a significant proportion of malignant cancers. While radiotherapy (RT) improves prognosis, it can also lead to side effects such as radiation‐induced pneumonitis (RP). Since SIRT6 is involved in DNA repair, energy metabolism and inflammation, this study aims to investigate the expression of SIRT6 in lymphocytes as a ...
Fengyuan Yu, Zheng Gong, Yuan Li, Danial F. Naseem, Chen Li, Miaowei Wen, Bingying Zhao, Zhezhe Xu, Shanshan Zhang, Rukun Zang, Ailu Wu, Qingxin Han, Shuhui Wu, Hongwei Li, Yipeng Song   +14 more
wiley   +1 more source

Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience

British Journal of Haematology, Volume 206, Issue 6, Page 1683-1688, June 2025.
Summary There is still no standard of care and unmet medical needs in refractory/advanced VEXAS (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X‐linked, autoinflammatory manifestations and somatic) syndrome with or without associated haematological neoplasm.
Maël Heiblig, Adriana Plesa, Juliet Tantot, Yvan Jamilloux, Hélène Labussière‐Wallet, Pierre Sujobert   +5 more
wiley   +1 more source

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

Biologics: Targets & Therapy, 2009
Kylie Thaler1, Divya V Chandiramani2, Richard A Hansen2, Gerald Gartlehner11Department for Evidence-based Medicine and Clinical Epidemiology, Danube University Krems, Krems, Austria; 2UNC Eshelman School of Pharmacy, University of North Carolina
Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al   +3 more
doaj  

Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study

Clinical &Experimental Allergy, Volume 55, Issue 6, Page 481-492, June 2025.
ABSTRACT Background Chronic urticaria (CU) treatment with omalizumab is considered safe in short‐term studies. Large real‐world studies focusing on the long‐term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab‐treated CU patients in a large long‐term daily practice ...
Reineke Soegiharto, Esther Van der Wind, Mehran Alizadeh Aghdam, Jennifer A. Sørensen, Esmee Van Lindonk, Ferhan Bulut Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Kiefer, André C. Knulst, Marcus Maurer, Carla Ritchie, Michael Rudenko, Emek Kocatürk, Roberta Fachini Jardim Criado, Stamatis Gregoriou, Tatjana Bobylev, Andreas Kleinheinz, Shunsuke Takahagi, Michihiro Hide, Ana M. Giménez‐Arnau, Andaç Salman, Rabia Oztas Kara, Bahar Sevimli Dikicier, Martijn B. A. Van Doorn, Simon F. Thomsen, Juul M. P. A. Van den Reek, Heike Röckmann   +27 more
wiley   +1 more source

Anakinra [PDF]

Reactions Weekly, 2021
openaire   +1 more source

The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community‐Acquired Pneumonia (CAP)

The Clinical Respiratory Journal, Volume 19, Issue 6, June 2025.
This study evaluated 204 hospitalised CAP patients, measuring suPAR, CRP, PCT, CURB‐65 and PSI at admission, with outcomes tracked over 365 days. SuPAR showed limited value in predicting CAP severity compared to CURB‐65 and PSI. ABSTRACT Background Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients,
Lisa Hessels, Ruud Duijkers, Marianne Schoorl, Lotte Terpstra, Willemien Thijs, Wim Boersma   +5 more
wiley   +1 more source

Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study

Therapeutic Advances in Hematology
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening, hyperinflammatory syndrome for which etoposide-based regimens have historically been the standard of care.
Benjamin J. Lee
doaj   +1 more source